Advice

in the absence of a submission from the holder of the marketing authorisation:

cenegermin (Oxervate®) is not recommended for use within NHSScotland.

Indication under review: Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Download full details356KB (PDF)

Download

Medicine details

Medicine name:
cenegermin (Oxervate)
SMC ID:
SMC2124
Indication:
Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.
Pharmaceutical company
Dompe UK Ltd
BNF chapter
Eye
Submission type
Non submission
Status
Not recommended
Date advice published:
08 October 2018